Nghiên cứu 3D-QSAR và công nghệ docking phân tử các dẫn xuất azaindole như chất ức chế kinase Aurora B

Moriarty KJ, Koblish HK, Garrabrant T, Maisuria J, Khalil E, Ali F, Petrounia IP, Crysler CS, Maroney AC, Johnson DL, RAG Jr (2006) The synthesis and SAR of 2-amino-pyrrolo[2, 3-d]pyrimidines: a new class of Aurora-A kinase inhibitors. Bioorg Med Chem Lett 16:5778–5783 Bavetsias V, Sun C, Bouloc N, Reynisson J, Workman P, Linardopoulos S, McDonald E (2007) Hit generation and exploration: imidazo[4, 5-b]pyridine derivatives as inhibitors of Aurora kinases. Bioorg Med Chem Lett 17:6567–6571 Zhong M, Bui M, Shen W, Baskaran S, Allen DA, Elling RA, Flanagan WM, Fung AD, Hanan EJ, Harris SO, Heumann SA, Hoch U, Ivy SN, Jacobs JW, Lam S, Lee H, McDowell RS, Oslob JD, Purkey HE, Romanowsky MJ, Silverman JA, Tangonan BT, taverna P, Yang W, Yoburn JC, Yu CH, Zimmerman KM, O’Brein T, Lew W (2009) 2-Aminobenzimidazoles as potent Aurora kinase inhibitors. Bioorg Med Chem Lett 19:5158–5161 Mortlock AA, Foote KM, Heron NM, Jung FH, Pasquet G, Lohmann J-JM, Warin N, Renaud F, Savi CD, Roberts NJ, Johnson T, Dousson CB, Hill GB, Perkins D, Hatter G, Wilkinson RW, Wedge SR, Heaton SP, Odedra R, Keen NJ, Crafter C, Brown E, Thompson K, Brightwell S, Khatri L, Brady MC, Kearney S, McKillop D, Rhead S, Parry T, Green S (2007) Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of Aurora B kinase. J Med Chem 50:2213–2224 Kishore AH, Vedamurthy BM, Mantelingu K, Agrawal S, Reddy BAA, Roy S, Rangappa KS, Kundu TK (2008) Specific small-molecule activator of Aurora kinase A induces autophosphorylation in a cell-free system. J Med Chem 51:792–797 Medina JR, Grant SW, Axten JM, Miller WH, Donatelli CA, Hardwicke MA, Oleykowski CA, Liao Q, Plant R, Xiang H (2010) Discovery of a new series of Aurora inhibitors through truncation of GSK1070916. Bioorg Med Chem 20:2552–2555 Adams ND, Adams JL, Burgess JL, Chaudhari AM, Copeland RA, Donatelli CA, Drewry DH, Fisher KE, Hamajima T, Hardwicke MA, Huffman WF, Koretke-Brown KK, Lai ZV, McDonald OB, Nakamura H, Newlander KA, Oleykowski CA, Parrish CA, Patrick DR, Plant R, Sarpong MA, Sasaki K, Schmidt SJ, Silva DJ, Sutton D, Tang J, Thompson CS, Tummino PJ, Wang JC, Xiang H, Yang J, Dhanak D (2010) Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem 53:3973–4001 Coumar MS, Wu JS, Leou JS, Tan UK, Chang CY, Chang TY, Lin WH, Hsu JTA, Chao YS, Wu SY, Hsieh HP (2008) Aurora kinase A inhibitors: identification, SAR exploration and molecular modeling of 6, 7-dihydro-4H-pyrazolo-[1, 5-a]pyrrolo[3, 4-d]pyrimidine-5, 8-dione scaffold. Bioorg Med Chem Lett 18:1623–1627 Bebbington D, Binch H, Charrier J-D, Everitt S, Fraysse D, Golec J, Kay D, Knegtel R, Mak C, Mazzei F, Miller A, Mortimore M, O’Donnell M, Patel S, Pierard F, Pinder J, Pollard J, Ramaya S, Robinson D, Rutherford A, Studley J, Westcott J (2009) The discovery of the potent aurora inhibitor MK-0457 (VX-680). Bioorg Med Chem Lett 19:3586–3592 Foote KM, Mortlock AA, Heron NM, Jung FH, Hill GB, Pasquet G, Brady MC, Green S, Heaton SP, Kearney S, Keen NJ, Odedra R, Wedge SR, Wilkinson RW (2008) Synthesis and SAR of 1-acetanilide-4-aminopyrazole-substituted quinazolines: selective inhibitors of Aurora B kinase with potent anti-tumor activity. Bioorg Med Chem 18:1901–1909 Li M, Jung A, Ganswindt U, Marini P, Friedl A, Daniel PT, Lauber K, Jendrossek V, Belka C (2010) Aurora kinase inhibitor ZM447439 induces apoptosis via mitochondrial pathways. Biochem Pharm 79:122–129 Rawson TE, Ruth M, Blackwood E, Burdick D, Corson L, Dotson J, Drummond J, Fields C, Georges GJ, Goller B, Halladay J, Hunsaker T, Kleinheinz T, Krell HW, Li J, Liang J, Limberg A, McNutt A, Moffat J, Phillips G, Ran Y, Safina B, Ultsh M, Walker L, Wiesmann C, Zhang B, Zhou A, Zhu BY, Ruger P, Cochran AG (2008) A pentacyclic Aurora kinase inhibitor (AKI-001) with high in vivo potency and oral bioavailability. J Med Chem 51:4465–4475 Myrianthopoulos V, Magiatis P, Ferandin Y, Skaltsounis AL, Meijer L, Mikros E (2007) An integrated computational approach to the phenomenon of potent and selective inhibition of Aurora kinases B and C by a series of 7-substituted indirubins. J Med Chem 50:4027–4037 Aihara A, Tanaka S, Yasen M, Matsumura S, Mitsunori Y, Murakata A, Noguchi N, Kudo A, Nakamura N, Ito K, Arii S (2010) The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. J Hepatol 52:63–71 Aliagas-Martin I, Burdick D, Corson L, Dotson J, Drummond J, Fields C, Huang OW, Hunsaker T, Kleinheinz T, Krueger E, Liang J, Moffat J, Phillips G, Pulk R, Rawson TE, Ultsch M, Walker L, Wiesmann C, Zhang B, Zhu BY, Cochran AG (2009) A class of 2, 4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B. J Med Chem 52:3300–3307 Howard S, Berdini V, Boulstridge JA, Carr MG, Cross DM, Curry J, Devine LA, Early TR, Fazal L, Gill AL, Heathcote M, Maman S, Matthews JE, McMenamin RL, Navarro EF, O’Brien MA, O’Reilly M, Rees DC, Reule M, Tisi D, Williams G, Vinkovic M, Wyatt PG (2009) Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent Aurora kinase activity. J Med Chem 52:379–388 Sivan SK, Manga V (2010) Molecular docking and 3D-QSAR studies on triazolinone and pyridazinone, non-nucleoside inhibitor of HIV-1 reverse transcriptase. J Mol Model 16:1169–1178 Sybyl 8.1, Tripos Inc, St. Louis, MO, http://tripos.com/ Song QL, Sun PH, Chen WM (2010) Exploring 3D-QSAR for ketolide derivatives as antibacterial agents using CoMFA and CoMSIA. Lett Drug Des Discovery 7:149–159 Zhang N, Zhong R (2010) Docking and 3D-QSAR studies of 7-hydroxycoumarin derivatives as CK2 inhibitors. Eur J Med Chem 45:292–297 Ibrahim DA, El-Metwally AM (2010) Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors. Eur J Med Chem 45:1158–1166 Hu R, Barbault F, Delamar M, Zhang R (2009) Receptor- and ligand-based 3D-QSAR study for a series of non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem 17:2400–2409 Murumkar PR, Gupta SD, Zambre VP, Giridhar R, Yadav MR (2009) Development of predictive 3D-QSAR CoMFA and CoMSIA models for β-aminohydroxamic acid-derived tumor necrosis factor-α converting enzyme inhibitors. Chem Biol Drug Des 73:97–107 Lu XY, Chen YD, Sun NY, Jiang YJ, You QD (2010) Molecular-docking-guided 3D-QSAR studies of substituted isoquinoline-1, 3-(2H, 4H)-diones as cyclin-dependent kinase (CDK4) inhibitors. J Mol Model 16:163–173 Sun J, Cai S, Yan N, Mei H (2010) Docking and 3D-QSAR studies of influenza neuraminidase inhibitors using three-dimensional holographic vector of atomic interaction field analysis. Eur J Med Chem 45:1008–1014 Pan J, Liu GY, Cheng J, Chen XJ, Ju XL (2010) CoMFA and molecular docking studies of benzoxazoles and benzothiazoles as CYP450 1A1 inhibitors. Eur J Med Chem 45:967–972 Pan X, Tan N, Zeng G, Huang H, Yan H (2010) 3D QSAR studies on ketoamides of human cathepsin K inhibitors based on two different alignment methods. Eur J Med Chem 45:667–681 Cichero E, Cesarini S, Mosti L, Fossa P (2010) CoMFA and CoMSIA analyses on 4-oxo-1, 4-dihydroquinoline and 4-oxo-1, 4-dihydro-1, 5-, -1, 6- and -1, 8-naphthyridine derivatives as selective CB2 receptor agonists. J Mol Model 16:677–691 Li Y, Wang YH, Yang L, Zhang SW, Liu CH, Yang SL (2005) Comparison of steroid substrates and inhibitors of P-glycoprotein by 3D-QSAR analysis. J Mol Struct 733:111–118